China
Africa
Explore chapters and articles related to this topic
Granuloma Annulare (Localized)
Published in Charles Theisler, Adjuvant Medical Care, 2023
Topical or oral vitamin E are possible alternatives to consider in the treatment of recalcitrant generalized granuloma annulare.3Vitamin D: In one instance, a case of granuloma annulare resolved with oral-activated vitamin D. The patient was a 40-year-old woman who had a 12-year history of the disease on her legs.4 She was effectively treated with .25 micrograms of vitamin D3 per day.
Inflammatory dermatoses affecting the nail
Published in Eckart Haneke, Histopathology of the NailOnychopathology, 2017
Granuloma annulare (GA) is a fairly common granulomatous disorder of the skin of unknown etiology. Clinically, rings of small, flat, flesh-colored nodules, approximately 3 to 5 mm in diameter, are seen mainly on the extremities of young persons. Apart from the typical form, other variants of granuloma annulare exist, for example, generalized granuloma annulare, perforating GA, and subcutaneous GA. The distal digits are very rarely affected.187 Nail fold involvement may occur.
Methotrexate treatment of generalized granuloma annulare: a retrospective case series
Published in Journal of Dermatological Treatment, 2018
Fludiona Naka, Bruce E. Strober
The prevalence of GA is not known, however, localized GA is the most common clinical variant, accounting for up to 75% of all GA patients (1,23). Localized GA typically presents on the dorsal and lateral hands and feet within the first three decades of life with higher incidence among women (1). The condition tends to self-resolve within two months to two years, but recurrence rates are as high as 40% (6,22,24). Approximately, 15% of patients with GA have generalized disease (25). Generalized granuloma annulare (GGA) is characterized by 10 or more lesions distributed symmetrically on the trunk and extremities. Age distribution tends to be bimodal. Some cases occur in children under the age of 10 but the majority present in adults between the 4th and 7th decades of life (1,4).
Two cases of lupus miliaris disseminatus faciei successfully treated with oral tofacitinib
Published in Journal of Dermatological Treatment, 2023
Although LMDF is self-limiting, more effective treatment is needed to shorten the disease course and reduce the risk of scar formation. Oral JAK inhibitors have been reported successfully used in granulomatous diseases such as cutaneous sarcoidosis and generalized granuloma annulare [3,4]. Thus, we pustulate that tofacitinib which blocking JAK-STAT signal may be effective in treating LMDF. Very recently, a report revealed that topical JAK inhibitor-ruxolitinib cream is effective for LMDF [5]. Our successful attempt shows that oral JAK inhibitors as monotherapy or in combination with other drugs are promising for LMDF. Studies with large sample are needed to reveal the efficacy and safety of oral JAK inhibitors for the treatment of LMDF.